# Patent

## Title
Methods of using poxvirus p35 as a chemokine inhibitor and compositions

## Abstract

A pharmaceutical composition comprising, as an active ingredient, a lens antigen which induces a lens cell damaging immune response or a microorganism capable of expressing a lens antigen which induces a lens cell damaging immune response. The pharmaceutical composition of the present invention containing, as an active ingredient, a lens antigen or a microorganism capable of expressing said antigen shows markedly superior inhibitory effects on the increase of an anti-lens protein antibody titer. Therefore, it most probably treats or prevents cataract effectively, and delays onset of cataract. Thus, the composition is extremely useful for cataract patients and reserve patients of cataract.

## Background
1. Field of the Invention

The present invention relates to a pharmaceutical composition containing, as an active ingredient, a lens antigen or a microorganism capable of expressing said antigen. More particularly, the present invention relates to an inhibitor to the increase of antibodies against a lens protein. The present invention further relates to an agent for the therapy, prophylaxis or retardation of onset of cataract.

2. Description of Related Art

Cataract is a serious disease associated with gradual loss of eyesight caused by a lens which became opaque due to various factors. It comes out with a symptom of paropsis caused by the opacity of the lens.

Cataract has so far been treated by the administration of various pharmaceutical agents. However, administration of such agents is not entirely satisfactory, partly because the etiology of cataract has not been fully elucidated. Consequently, the treatment of cataract today ultimately relies on surgical one. The surgical treatment comprises either removal of lens nucleus and lens cortex to the outside of the membrane of the lens, or enucleation of the entire opaque lens out from the eye. However, surgical treatments often induce complications and they are burdensome to patients, since incision and suture of the cornea are inevitable even when operated with the state-of-the-art surgery technique.

To sum, the etiology of cataract has not been fully elucidated and agents for therapy thereof are not satisfactory. A surgical treatment accompanies great burden on patients.

It is therefore an object of the present invention to provide a novel pharmaceutical composition useful for the therapy of cataract and the like.

It has now been found according to the present invention that administration of a lens antigen which induces lens cell damaging immune responses (hereinafter such antigen is sometimes referred to simply as lens antigen of the present invention) leads to a suppression of the increase of anti-lens protein antibodies in sera. As shown in Experimental Examples 1 and 2 to be mentioned later, cataract is caused by lens epithelial cell damage due to autoimmunity by lens protein. Hence, the lens antigen of the present invention or a microorganism capable of expressing said antigen is useful for the therapy, prophylaxis or retardation of onset of cataract.

Thus, the present invention provides a pharmaceutical composition containing, as an active ingredient, a lens antigen capable of inducing lens cell damaging immune responses; particularly, an inhibitor of the increase of anti-lens protein antibodies. More specifically, the present invention provides a pharmaceutical composition comprising a lens antigen containing an epitope having an amino acid sequence of amino acid Nos. 2-6 depicted in Sequence Listing, SEQ ID NO:1, or amino acid Nos. 162-166 depicted in Sequence Listing, SEQ ID NO:8. Particularly, provided is a pharmaceutical composition wherein the lens antigen is a lens crystallin or a lens membrane peptide. The lens membrane peptide of the present invention includes all peptides present in or on the lens membrane, and includes peptides constituting a lens membrane protein or a receptor present in lens membrane.

The present invention further provides a pharmaceutical composition containing an animal lens homogenate as an active ingredient.

The present invention moreover provides a pharmaceutical composition containing, as an active ingredient, a microorganism capable of the expressing lens antigen which induces lens cell damaging immune responses; particularly, an inhibitor of increase of anti-lens protein antibodies, which is more particularly a pharmaceutical composition containing said active ingredient in a form suitable for intestinal administration.

The present invention still further provides the above-mentioned pharmaceutical composition for the therapy, prophylaxis or retardation of onset of cataract.

The present invention also provides a method for suppressing an increase of anti-lens protein antibodies, comprising administering an active ingredient selected from the group consisting of a lens antigen which induces a lens cell damaging immune response and a microorganism capable of expressing a lens antigen which induces a lens cell damaging immune response.

The present invention moreover provides use of an active ingredient selected from the group consisting of a lens antigen which induces a lens cell damaging immune response and a microorganism capable of expressing a lens antigen which induces a lens cell damaging immune response, for the preparation of an inhibitor of the increase of anti-lens protein antibodies.

FIG. 1(A) and 1(B) are light microscopic photographs showing lens epithelial cells at five weeks after initial immunization of mice with .beta..sub.H -crystallin.

FIG. 2 is a graph showing anti-.beta..sub.H -crystallin antibody titers, as determined by ELISA, of sera (diluted 10,000-fold) from mice at five weeks after initial immunization.

FIG. 3 is a graph showing titers of anti-.beta.-crystallin antibodies in sera (diluted 10,000-fold) from mice at two, three, four or five weeks after the first immunization, as determined by ELISA with regard to mice orally administered with a lens homogenate from 26 days before immunization to the day of the first immunization.

FIG. 4 is a graph showing titers of anti-.beta.-crystallin antibodies in sera (diluted 10,000-fold) from mice at two, three, four or five weeks after the first immunization, as determined by ELISA with regard to mice orally administered with a lens homogenate from 26 days before immunization to 34 days after the first immunization.

FIG. 5 is a graph showing titers of anti-.beta.-crystallin antibodies in sera (diluted 10,000-fold) from mice at two, three, four or five weeks after the first immunization, as determined by ELISA with regard to mice orally administered with a lens homogenate from the day of the first immunization to 34 days from the first immunization.

In the present invention, by a lens antigen is meant an antigenic substance in the lens or one having the same antigenic determinant (epitope) with that possessed by said antigenic substance. Examples thereof include proteins present in lens tissues, such as lens crystallins (e.g., .alpha.-crystallins, .beta.-crystallins and .gamma.-crystallins), lens membrane proteins e.g., major intrinsic protein (MIP) and epidermal epithelial protein (EEP)! and constitutive peptide of receptor present in lens membrane. These may be naturally occurring or synthetic. A naturally occurring one may be an isolated material or a material containing the same. Such material containing an isolated material includes, for example, lens homogenate and lens epithelial cell homogenate.

The naturally occurring lens antigen is not limited in terms of derivation, and may be derived from mammals such as human, cow, horse, swine and sheep, or from a microorganism capable of expressing the lens antigen.

A lens crystallin is a typical lens antigen which induces lens cell damaging immune responses. An administration of the lens antigen of the present invention to mammals before and/or after immunization with crystallin leads to induction of immunological tolerance which enables suppression of the increase in anti-lens protein antibody titer of sera. The suppressive effects are described in detail in the following Experimental Example 7.

The epitope of the lens antigen of the present invention is not particularly limited as long as it has an amino acid sequence affording immunogenicity to produce a lens cell damaging antibody. Specific examples include amino acid sequence (amino acid Nos. 2-6) depicted in Sequence Listing, SEQ ID NO:1 and amino acid sequence (amino acid Nos. 162-166) depicted in Sequence Listing, SEQ ID NO:8. The peptides having such an amino acid sequence include human .beta.-crystallins derived from lens, and topoisomerases of Escherichia coli, Salmonella and yeast, 17 kD protein of barley stripe mosaic virus, HF-1 protein of Haemophilus influenzae and the like derived from non-lens sources. Identification of epitope is described in detail later in Experimental Examples 3 and 4.

In the present invention, the term "microorganism" encompasses a wide range of microorganisms inclusive of viruses. Specific examples include procaryotic cells (e.g., bacteria and Actinomycetes) and fungi (e.g., filamentous fungus, yeast, Myxomycetes, Basidiomycetes and Zygomycetes), some algae, protozoa, virus and the like. These include not only wild ones but also those artificially constructed by known recombinant technology. Typical examples thereof include infectious microorganisms such as bacteria (e.g., Neisseria meningitidis, Vibrio cholerae and Escherichia coli) and viruses (e.g., Epstein-Barr virus and cytomegalovirus), since the proteins expressed thereby have the same epitope as that possessed by human crystallins.

Said microorganisms may be attenuated and used in the present invention. Attenuation can be performed by a method known Per se, such as heat and formalin treatments.

The microorganisms artificially obtained by genetic recombination include host microorganisms transformed with a recombinant vector containing a DNA encoding peptide which is a lens antigen of the present invention. The host microorganism may be, for example, bacteria such as Escherichia coli, genus Bacillus and lactic acid bacterium, or yeast. The recombinant vector into which said DNA is to be incorporated is not subject to any particular limitation as long as it can be replicated or self-proliferated in the above-mentioned various hosts and can express said incorporated DNA in the host. Examples thereof include plasmid DNA and phage DNA. Specific examples include pUC18, pUC19, pSP64 and the like as plasmid vectors for expression in Escherichia coli; pPL608, pAM .alpha.1 and the like for expression in Bacillus subtilis; and YEp51, pAAH5, pYE4 and the like for expression in yeast. As a phage expression vector, exemplified are .lambda.gt11, ZAPII and the like.

The pharmaceutical composition of the present invention may be, for example, an inhibitor of the increase of anti-lens protein antibodies, or an agent for therapy, prophylaxis or retardation of onset of cataract.

The lens antigen can be prepared into a preparation for administration by a conventional method generally used for formulation of a preparation. When said pharmaceutical composition is for oral administration, the preparation is desirably provided in the form suitable for absorption from digestive tract.

Examples of oral solid preparation include tablets, capsules, granules, powders and the like. These preparations may contain various components to be added according to the preparation, such as binders (e.g., syrup, gum arabic, gelatin, sorbit, tragacanth gum and polyvinylpyrrolidone); excipients (e.g., lactose, corn starch, calcium phosphate, sorbit and glycine); lubricants (e.g., magnesium stearate, talc, polyethylene glycol and silica); disintegrators (e.g., potato starch); wetting agents (e.g., sodium lauryl sulfate); dispersing agents; thickeners; flavors; emulsifiers; and the like. Tablets may be coated by a known method.

While the amount of the lens antigen to be contained in solid preparations may vary depending on the number of doses, presence or otherwise of other efficacious ingredients and so on, it is generally 0.1-500 mg/tablet.

Oral liquid preparation may be, for example, aqueous or oily suspensions, solutions, syrups or elixirs. The liquid preparations may contain additives of general use, such as suspending agents (e.g., sorbit syrup, methylcellulose, syrup, gelatin, hydroxyethylcellulose, carboxymethylcellulose and aluminum stearate gel); emulsifiers (e.g., lecitin and sorbitan monooleate); nonaqueous vehicles (e.g., almond oil, fractionated coconut oil, oily ester, propylene glycol and ethanol); preservatives; and the like.

While the amount of the lens antigen to be contained in the liquid preparations may vary depending on the number of doses, presence or otherwise of other efficacious ingredients and so on, it is generally 1 mg-100 g/100 ml.

The oral preparation may be a solid preparation to be dissolved in a suitable vehicle, such as water, when in use.

When the pharmaceutical composition is an intravenous preparation, pH adjusting agents, buffers, stabilizers, preservatives, solubilizers and the like may be added to the lens antigen as necessary, and the mixture is prepared into an intravenous preparation by a conventional method.

The lens antigen of the present invention is administered orally (inclusive of intestinal administration, intragastric administration and inhalation) or parenterally (e.g., intravenous administration). While the dose thereof may vary depending on titers of anti-lens protein antibodies in sera, degree of progression of cataract, severity of the disease, tolerance to drugs and the like, it is generally 0.1 mg-10 g, preferably 1 mg-1 g, more preferably 10 mg-100 mg in an antigen amount daily for an adult by oral administration, which may be administered in a single dose or several doses. The preparation may be prepared in a most suitable form according to the administration route.

Inasmuch as the lens antigen is a biological component, it is low toxic and causes less side-effects.

When the lens antigen of the present invention is derived from a microorganism, the microorganism itself may be administered. Particularly, it may be administered in the form of an intestinal preparation and administered particularly into small intestine.

Said microorganism can be provided as an oral preparation suitable for maintaining viable counts in the preparation and for easy absorption from intestine, which is in the form of a solid preparation or liquid preparation. A method for maintaining viable counts in the preparation, namely, a method for stabilization of the microorganism includes, for example, dispersion of microorganism in anhydrous media, addition of stabilizers to the preparation, coating of microorganism, and the like, which is selected as appropriate according to the form of the preparation.

Examples of the solid preparation include granules, powders, tablets, capsules and the like. Such preparations may contain suitable components depending on the preparation, such as binders (e.g., polyvinylpyrrolidone, hydroxypropylcellulose, sucrose fatty acid ester, gum arabic, gelatin and pullulan); excipients (e.g., lactose and corn starch); lubricants (e.g., magnesium stearate, talc, polyethylene glycol and silica); disintegrators (e.g., potato starch); wetting agents (e.g., sodium lauryl sulfate); adjuvants; and the like.

To make the preparation enteric-coated and to stabilize the microorganism, for example, the following coating may be preferably applied to the solid preparation.

The coating agent may be a liposoluble substance known per se, such as synthetic and semisynthetic substances (e.g., carboxymethyl-cellulose, hydroxymethylcellulose phthalate and Eudragit); natural substances such as shellac; admixture of copolymer of methacrylic acid and ethyl acrylate, and copolymer of methacrylic acid and methyl methacrylate; and the like.

A stabilizer may be contained to stabilize the microorganism. Examples of the stabilizer include polyvinylpyrrolidone, sodium carboxymethylcellulose, sodium polyacrylate, sodium arginate and the like.

While the amount of the microorganism in the solid preparation may vary depending on the number of doses, the presence or otherwise of other efficacious ingredients and the like, the viable count is generally 10.sup.3 -10.sup.10 cells/tablet.

Examples of oral liquid preparation include aqueous or oily suspensions, solutions, syrups, pastes, gels, elixirs and the like. Such liquid preparation can be produced by a method including addition of suspending agents such as arginic acid or sodium salt thereof, processed starches such as dextrin, pectin, carrageenan, locust bean gum, guar gum, cod gum, xanthane gum, gelatin and the like to water or a solution containing a microorganism, a method including dispersing, in a solution, a complex of microorganism and lipid in the form of a liposome, emulsion or micelle, and the like. It is also preferable that the microorganism be stabilized in a liquid preparation, and particularly preferred is the microorganism uniformly dispersed in the preparation.

Said liquid preparation may contain conventional additives, such as suspending agents, emulsifiers, nonaqueous vehicles, preservatives, adjuvants, and the like.

While the amount of the microorganism in the liquid preparation may vary depending on the number of doses, the presence or otherwise of other efficacious ingredients and the like, its viable count is generally 1.times.10.sup.3 -5.times.10.sup.10 cells/100 ml.

The oral preparation may be a solid preparation to be dissolved in a suitable vehicle, such as water, when in use.

While the dose of the microorganism capable of expressing the lens antigen of the present invention may vary depending on titers of anti-lens protein antibodies in sera, degree of progression of cataract, severity of the disease, tolerance to drugs, as well as expression efficiency of said antigen and the like, it is generally 1 mg-100 g, preferably 10 mg-10 g, more preferably 100 mg-1 g in a raw material weight of the microorganism daily for an adult, which may be administered in a single dose or plural doses. The preparation may be prepared into a most suitable form according to the administration route.

The possibility that the lens antigen of the present invention and microorganism capable of expressing the lens antigen of the present invention may have effects of therapy, prophylaxis or retardation of onset of cataract is strongly suggested from Experimental Examples 2 and 7 to be described later.

The present invention is further explained in detail by way of Examples in the following, and the effects of the present invention are clarified by Experimental Examples. These are mere examples which in no way limit the scope of the present invention. homogenate or crystallin

Lewis rats (female, a year old) were divided into two groups (each containing four rats), and immunized five times with an emulsion of lens homogenate (first group) or .beta.-crystallin (second group), and complete Freund adjuvant (CFA). As a result, severe lens epithelial cell damage was observed in all animals of the first and the second groups at 21 days after the first immunization. The ocular tissues of the rats of the control group, which were given an injection of a phosphate buffered saline (PBS)-CFA emulsion, were the same as those of untreated rats. From the above results, it was found that lens constituent components, preferably crystallins, particularly .beta.-crystallin, were effective immunogens which induced lens epithelial cell damage. epithelial cell damage by immunization with .beta.-crystallin

The antigen was narrowed down to a single .beta..sub.H -crystallin, and mice were immunized therewith.

Purified .beta..sub.H -crystallin (manufactured by Sigma) was dissolved in PBS, prepared into an emulsion with CFA at a ratio of 1:1, and adjusted to a final concentration of 1 mg/ml. Mice (C57BL, female, 6 months old) were immunized with said emulsion (100 .mu.l/animal). After the first immunization, four booster injections were given every other week. For boosters, the same procedure as above was followed except incomplete Freund adjuvant (IFA) was used instead of CFA. At 5 weeks after the first immunization, blood was taken from the mice. The mice were euthanized, and eyeballs were removed for histopathological examinations.

Light microscopic sections of the removed eyeballs were prepared and subjected to evaluation of lens epithelial cells. As a result, lens epithelial cell damage was found in the ocular tissues of immunized mice (FIG. 1).

The antibody titer against .beta..sub.H -crystallin in the collected sera was determined by enzyme-linked immunosorbent assay (ELISA). The antigen of .beta..sub.H -crystallin was immobilized on 96-well microtiter plates at a concentration of 10 .mu.g/ml. After blocking, the sera of the immunized mice were diluted to 10.sup.3 -10.sup.6 -fold and reacted with the antigen. After washing, alkaline phosphatase-conjugated goat anti-mouse IgG was reacted as a secondary antibody. After washing, antibody titer was determined by color development of substrate solution of paranitrophenylphosphoric acid (pNPP). As a result, the antibody titer against .beta..sub.H -crystallin in the sera of the immunized mice was extremely higher than that of untreated mice and mice immunized with PBS-adjuvant emulsion (FIG. 2).

From the above results, it was found that lens epithelial cell damage appeared with increasing titers of antibodies against .beta..sub.H -crystallins. In other words, these results clearly suggest that the lens epithelial cell damage due to autoimmunity are concerned with the pathogenesis of cataract.

Fifteen kinds of oligopeptides (19 amino acid residues; sequence shown in Table 1) constituting human .beta.A.sub.3 -crystallins having a known amino acid sequence were synthesized by a conventional method, and subjected to competitive inhibition assay of .beta.A.sub.3 -crystallins and respective oligopeptides.

As the antigen, .beta.-crystallin (containing about 10% .beta.A.sub.3 -crystallin) was immobilized on microtiter plates at a concentration of 10 .mu.g/ml. After blotting, .beta.-crystallin monoclonal antibody (1 .mu.g/ml and respective oligopeptides were added and the mixture was reacted with antigen. After washing, alkaline phosphatase-conjugated goat anti-mouse IgG was reacted as a secondary antibody. After washing, competitive inhibitory activity of peptide against the antigen was determined by color development of substrate pNPP. As a result, peptide No. 1 showed a strong binding inhibitory effect on .beta.A.sub.3 -crystallin. This suggests that the binding site (epitope) of .beta.A.sub.3 -crystallin to the antibody was present in N terminal 19 amino acid residues (peptide No. 1). __________________________________________________________________________ Inhibitory effect on BA.sub.3 -crystallin-antibody binding by human BA.sub.3 -crystallin partial peptides (1) peptide No. amino acid sequence.sup.1) site.sup.2) binding inhibition.sup.3) __________________________________________________________________________ 1     METQAEQQELETLPTTKMA SEQ ID NO. 13 1-19 +++ 2     TTKMAQTNPTPGSLGPWKI SEQ ID NO. 14 15-33 - 3     GPWKITIYDQENFQGKRME SEQ ID NO. 15 29-47 - 4     GKRMEFTSSCPNVSERSFD SEQ ID NO. 16 43-61 - 5     ERSFDNVRSLKVESGAWIG SEQ ID NO. 17 57-75 - 6     GAWIGYEHTSFCGQQFILE SEQ ID NO. 18 71-89 - 7     QFILERGEYPRWDAWSGSN SEQ ID NO. 19 85-103 - 8     WSGSNAYHMERLMSFRPFG SEQ ID NO. 20 99-117 - 9     FRPFGSANHKESKMTIFEK SEQ ID NO. 21 113-131 - 10    TIFEKENFIGRQWEISDDY SEQ ID NO. 22 127-145 - 11    ISDDYPSLQAMGWFNNEVG SEQ ID NO. 23 141-159 - 12    NNEVGSMKIQSGAWVGYHY SEQ ID NO. 24 155-173 - 13    VCYHYLGYRGYQYILKCDH SEQ ID NO. 25 169-187 - 14    LKCDHHEGDYKHWREWGSH SEQ ID NO. 26 183-201 - 15    EWGSHAQTSQIQSIRRIQQ SEQ ID NO. 27 197-215 - __________________________________________________________________________ .sup.1) Amino acids are expressed by one letter symbols according to recommendation of IUPACIUB Commission on Biochemical Nomenclature. .sup.2) The amino acid number of Sequence Listing SEQ ID NO: 1. .sup.3) +++: inhibited binding by 50% at less than 250 .mu.g of peptide ++: inhibited binding by 50% at not less than 250 .mu.g and less than 500 .mu.g of peptide +: inhibited binding by 50% at not less than 500 .mu.g and less than 750 .mu.g of peptide -: no binding inhibitory effect

The N terminal region (peptide No. 1) of .beta.A.sub.3 -crystallin was cut into smaller units of 6 or 7 residues to synthesize three kinds of peptides (peptide Nos. 16, 17 and 18), which were subjected to competitive inhibition assay with .beta.A.sub.3 -crystallin in the same manner as in Experiment 1. As a result, only peptide No. 16 had .beta.A.sub.3 -crystallin binding inhibitory effect (Table 2). From these results, the presence of epitope in peptide No. 16 (sequence : METQAE) was suggested. __________________________________________________________________________ Inhibitory effect on BA.sub.3 -crystallin-antibody binding by human BA.sub.3 -crystallin partial peptides (2) peptide No. amino acid sequence.sup.1) site.sup.2) binding inhibition.sup.3) __________________________________________________________________________ 1     METQAEQQELETLPTTKMA SEQ ID NO. 13 1-19 +++ 16    METQAE SEQ ID NO. 28 1-6  ++ 17    QQELET SEQ ID NO. 29  7-12 - 18    LPTTKMA SEQ ID NO. 30 13-19 - __________________________________________________________________________ .sup.1) Amino acids are expressed by one letter symbols according to recommendation of IUPACIUB Commission on Biochemical Nomenclature. .sup.2) The amino acid number of Sequence Listing SEQ ID NO: 1. .sup.3) +++: inhibited binding by 50% at less than 250 .mu.g of peptide ++: inhibited binding by 50% at not less than 250 .mu.g and less than 500 .mu.g of peptide +: inhibited binding by 50% at not less than 500 .mu.g and less than 750 .mu.g of peptide -: no binding inhibitory effect

To identify the minimum unit of .beta.A.sub.3 -crystallin epitope, one residue of six amino acid residues of peptide No. 16 was substituted by isoleucine residue to give six kinds of analogs (peptide Nos. 19-24) of peptide No. 16. In the same manner as in Experiment 1, competitive inhibition assay of .beta.A.sub.3 -crystallins and these peptides was performed. As a result, five kinds of peptide No. 16 analogs except peptide No. 19 showed lower inhibitory activity on binding of .beta.A.sub.3 -crystallin to antibody as compared to peptide No. 16. Peptide No. 19 alone strongly inhibited binding of .beta.A.sub.3 -crystallin to antibody like peptide No. 16 (Table 3). These results suggest that the five consecutive amino acid residues (sequence: ETQAE) of peptide No. 16 except the first methionine was the epitope of .beta.A.sub.3 -crystallin. ______________________________________ Inhibitory effect on BA.sub.3 -crystallin-antibody binding by human BA.sub.3 -crystallin partial peptides analogs peptide No. amino acid sequence.sup.1), 2) binding inhibition.sup.3) ______________________________________ 16          METQAE (28)    ++ 19          IETQAE (2)     ++ 20          MITQAE (3)     + 21          MEIQAE (4)     + 22          METIAE (5)     + 23          METQIE (6)     + 24          METQAI (7)     - PBS (control) - ______________________________________ .sup.1) Amino acids are expressed by one letter symbols according to recommendation of IUPACIUB Commission on Biochemical Nomenclature. .sup.2) The numerals in parentheses show Sequence Listing SEQ ID Numbers wherein said sequences are depicted. .sup.3) +++: inhibited binding by 50% at less than 250 .mu.g of peptide ++: inhibited binding by 50% at not less than 250 .mu.g and less than 500 .mu.g of peptide +: inhibited binding by 50% at not less than 500 .mu.g and less than 750 .mu.g of peptide -: no binding inhibitory effect

Seventeen kinds of oligopeptides (17 amino acid residues; sequence shown in Table 4) constituting human .beta.B.sub.2 -crystallins having a known amino acid sequence were synthesized by a conventional method, and subjected to competitive inhibition assay of .beta.B.sub.2 -crystallins and respective oligopeptides in the same manner as in Experiment 1 of Experimental Example 3. As a result, peptide No. 38 had strong inhibitory effect on binding of .beta.B.sub.2 -crystallin. This suggests that the binding site (epitope) of .beta.B.sub.2 -crystallin to the antibody was present in 17 amino acid residues of peptide No. 38. __________________________________________________________________________ Inhibitory effect on BB.sub.2 -crystallin-antibody binding by human BB.sub.2 -crystallin partial peptides peptide No. amino acid sequence.sup.1) site.sup.2) binding inhibition.sup.3) __________________________________________________________________________ 25    MASDHQTQAGKPQSLNP SEQ ID NO. 31 1-17 - 26    QSLNPKIIIFEQENPQG SEQ ID NO. 32 13-29 - 27    ENFQGHSHELNGPCPNL SEQ ID NO. 33 25-41 - 28    PCPNLKETGVEKAGSVL SEQ ID NO. 34 37-53 - 29    AGSVLVQAGPWVGYEQA SEQ ID NO. 35 49-65 - 30    GYEQANCKGEQFVFEKG SEQ ID NO. 36 61-77 - 31    VFEKGEYPRWDSWTSSR SEQ ID NO. 37 73-89 - 32    WTSSRRTDSLSSLRPIK SEQ ID NO. 38 85-101 - 33    LRPIKVDSQEHKIILYE SEQ ID NO. 39 97-113 - 34    IILYENPNFTGKKMEII SEQ ID NO. 40 109-125 - 35    KMEIIDDDVPSFHAHGY SEQ ID NO. 41 121-137 - 36    HAHGYQEKVSSVRVQSG SEQ ID NO. 42 133-149 - 37    RVQSGTWVGYQYPGYRG SEQ ID NO. 43 145-161 - 38    PGYRGLQYLLEKGDYKD SEQ ID NO. 44 157-173 +++ 39    GDYKDSSDFGAPHPQVQ SEQ ID NO. 45 169-185 - 40    HPQVQSVRRIRDMQWHQ SEQ ID NO. 46 181-197 - 41    RIRDMQWHQRGAFHPSN SEQ ID NO. 47 189-205 - __________________________________________________________________________ .sup.1) Amino acids are expressed by one letter symbols according to recommendation of IUPACIUB Commission on Biochemical Nomenclature. .sup.2) The amino acid number of Sequence Listing SEQ ID NO: 1. .sup.3) +++: inhibited binding by 50% at less than 250 .mu.g of peptide ++: inhibited binding by 50% at not less than 250 .mu.g and less than 500 .mu.g of peptide +: inhibited binding by 50% at not less than 500 .mu.g and less than 750 .mu.g of peptide -: no binding inhibitory effect

A peptide obtained by dividing peptide No. 38 having a partial sequence of .beta.B.sub.2 -crystallin was synthesized and the epitope region was further narrowed down by the same method as used in Experiment 2 of Experimental Example 3. Further, the minimum unit of .beta.B.sub.2 -crystallin epitope was identified in the same manner as in Experiment 3 of Experimental Example 3. As a result, the epitope was found to be consecutive five amino acid residues of amino acid Nos. 162-166 (sequence : LQYLL) in the amino acid sequence (SEQ ID No:8) of .beta.B.sub.2 -crystallin. derivation peptides having the same epitope with human .beta.A.sub.3 -crystallin

A non-lens derivation peptide having the same epitope with that of .beta.A.sub.3 -crystallin, namely, the peptide having an amino acid sequence of ETQAE, was searched using a Gene Bank database. As a result, proteins of microorganisms such as Escherichia coli, Salmonella, yeast and virus were found to have the said amino acid sequence (Table 5).

In addition, sequence homology of non-lens derivation peptides and human crystallin other than said epitope sequence was searched to confirm homologous sequences of peptides derived from the three kinds of animals shown in Table 6 and crystallin. ______________________________________ Non-lens derivation proteins having the same epitope with that of human BA.sub.3 -crystallin microorganism          protein ______________________________________ Escherichia coli       topoisomerase.sup.1) yeast                  topoisomerase Salmonella             topoisomerase barley stripe mosaic virus (BSMV) 17 kD protein Haemophilus influenzae HF-1 protein ______________________________________ .sup.1) Topoisomerase of Escherichia coli contained amino acid sequence (GLTETQAEAILE, Sequence Listing, SEQ ID NO: 9) of peptide I used in this Experimental Example. ______________________________________ Non-lens derivation peptides having sequence homology with human crystallin besides epitope sequence of human BA.sub.3 -crystallin partial amino acid sequence of peptides containing homologous sequence organism        with crystallin.sup.1), 2), 3) ______________________________________ coxsackievirus  MQYHYLGRTGYT (10) nematode ( C. elegans) DFATIFEKNAFL (11) peptide II! baboon endogenous virus QKLGPWKRPVAY (12) peptide III! ______________________________________ .sup.1) Amino acids are expressed by one letter symbols according to recommendation of IUPACIUB Commission on Biochemical Nomenclature. .sup.2) The underlined sequences are homologous with human BA.sub.3crystallin. .sup.3) Numerals in parentheses show Sequence Listing SEQ ID Numbers wherein said sequences are depicted.

Mice were immunized with either the topoisomerase partial amino acid sequence (peptide I) of Escherichia coli listed in Table 5 or the two kinds of peptides (peptides II, III) shown in Table 6, and antibody titer was measured.

Mice (B6C3, female, a year old) were divided into four groups (each containing two mice) and immunized with 100 .mu.g/animal of one of peptides I-III. After the first immunization, booster injections (100 .mu.g/animal of each peptide) were given twice every two weeks. In the same manner as in Experimental Example 2, an emulsion of the antigen and adjuvant was prepared and used for immunization. At 5 weeks after the first immunization, blood was taken from the mice. The mice were euthanized, and eyeballs were removed. In the same manner as in Experimental Example 2, antibody titer was determined by ELISA, and light microscopic sections of ocular tissues were prepared and subjected to evaluation of lens epithelial cells.

As a result, all mice immunized with peptide I (inclusive of .beta.A.sub.3 -crystallin epitope) showed mild lens epithelial cell damage. The sera taken from the mice immunized with peptide I showed cross reactivity with .beta.-crystallin (Table 7). The other two kinds of peptides did not induce lens epithelial cell damage, nor did they show cross reactivity with .beta.-crystallin. ______________________________________ Expression of lens epithelial cell damage in mice immunized with peptides containing crystallin homologous sequence, and anti-crystallin antibody titer of sera frequency of lens epithelial antigen    antibody titer.sup.1) cell damage (%) ______________________________________ peptide I  1/10,000   100 peptide II 1/500      0 peptide III 1/500      0 PBS        1/500      0 (control) ______________________________________ .sup.1) The antibody titer is expressed as dilution ratio of sections whe absorbance at 405 nm doubled blank values. induces lens epithelial cell damage

Rat .beta.B.sub.2 -crystallin cDNA (Aaits, H. J. et al., Eur. J. Biochem., 183: 31-36, 1989) was subcloned into a commercially available expression vector pKK223-3 (manufactured by Pharmacia Biotech), and Escherichia coli JM105 (manufactured by Pharmacia Biotech) was transformed with said recombinant vector to express .beta.B.sub.2 -crystallin in the host Escherichia coli. Said transformed cells were incubated in an LB medium containing 30 .mu.g/ml of ampicillin at 37.degree. C. for 24 hr. Using Escherichia coli JM105 transformed with pKK223-3 as a control, the following experiment was performed.

Mice (B6C3, female, a year old) were divided into two groups (each containing four mice) and immunized with recombinant Escherichia coli .beta.-B.sub.2 -pKK (1,000 .mu.g/0.2 ml) which expresses .beta.B.sub.2 -crystallin. After the first immunization, booster injections (1,000 .mu.g/animal) were given twice every two weeks. The lenses were examined with a slit lamp every two weeks. At 7 weeks after the first immunization, blood was taken from the mice and cross reactivity was determined by ELISA in the same manner as in Experimental Example2.

The polypeptide sequences of .beta.-crystallin of mouse and rat were extremely similar, and .beta.A.sub.3 -crystallin and .beta.B.sub.2 -crystallin showed high homology of 90% or more including the epitope moiety.

All mice immunized with Escherichia coli .beta.-B.sub.2 -pKK which expressed .beta.B.sub.2 -crystallin showed lens epithelial cell damage at 7 weeks after the first immunization. The lymphonodus cells of mice immunized with Escherichia coli which expressed .beta.B.sub.2 -crystallin showed cross reactivity with .beta.-crystallin (Table 8). Moreover, the sera antibodies against .beta.B.sub.2 -crystallin showed increase in these mice. In contrast, the mice immunized with control Escherichia coli JM105 (incapable of expressing .beta.B.sub.2 -crystallin) showed no cross reactivity of lyphocytes or an increase in antibody titer of the sera. The lenses of the mice of the control group did not display abnormality. From the foregoing results, it was evident that autoantigen expressed by Escherichia coil destroyed immunological tolerance and induced lens epithelial cell damage. ______________________________________ Expression of lens epithelial cell damage in mice immunized with recombinant Escherichia coli which expressed B-crystallin, and anti-crystallin antibody titer of sera frequency of lens epithelial antigen     antibody titer.sup.1) cell damage (%) ______________________________________ Escherichia coli 1/2,000     100 (B-B.sub.2 -pKK) capable of expressing BB.sub.2 -crystallin Escherichia coli 1/500       0 (JM105) incapable of expressing BB.sub.2 -crystallin ______________________________________ .sup.1) The antibody titer is expressed as dilution ratio of sections whe absorbance at 405 nm doubled blank values. mice immunized by oral administration of lens homogenate

Male and female C57BL mice (15-16 months old) were divided into a lens group and a BSA group, and immunized with bovine .beta.-crystallin. Bovine lens was homogenized with phosphate buffered saline (PBS) to the protein amount-of 20 mg/ml and orally administered to the lens group at 0.2 ml/animal (4 mg/animal) once every four days from 26 days before the first immunization to the day of the first immunization. As a control protein, bovine serum albumin (BSA) was dissolved in PBS to 20 mg/ml and orally administered to the BSA group in the same manner as in the lens group.

Male and female C57BL mice (15-16 months old) were divided into a PBS group, a lens group and a BSA group, and immunized with bovine .beta.-crystallin. In the same manner as in Experiment 1, the lens group and BSA group underwent oral administration once every four days from 26 days before the first immunization to 34 days after the first immunization. PBS (0.2 ml/animal) was orally administered to the PBS group.

Male and female C57BL mice (15-16 months old) were divided into a lens group and a BSA group, and immunized with bovine .beta.-crystallin. In the same manner as in Experiment 1, the lens group and BSA group underwent oral administration once every four days from the day of the first immunization to 34 days after the first immunization.

.beta.-Crystallin was isolated from bovine lens and prepared into an emulsion with CFA at a ratio of 1:1. The .beta.-crystallin (1 mg/ml) was administered subcutaneously from the tail of the mice of Experiments 1-3 by 0.1 ml/animal (0.1 mg/animal) for immunization. After the first immunization, booster injections were given twice every two weeks. For boosters, the same procedure as above was followed except that IFA was used instead of CFA. At every other week after the first immunization, blood was taken from the mice and antibody titer of sera against .beta.-crystallin was determined by ELISA in the same manner as in Experimental Example 2.

With respect to each experiment, antibody titers of sera against antigens (.beta.-crystallins) at 3, 4 and 5 weeks after the first immunization are shown in FIGS. 3-5. The antibody titers of the sera from C57BL mice immunized with .beta.-crystallin elevated at 3 and 4 weeks after the first immunization in Experiments 1-3, with the highest peak present at 5 weeks after the first immunization. In Experiment 2, mice underwent oral administration before and after the first immunization. The antibody titers of the lens group administered with lens homogenate showed noticeably lower values than the BSA group (control) at 4 and 5 weeks after the first immunization (FIG. 4). In Experiment 1, mice underwent oral administration before the first immunization, and in Experiment 3, mice underwent oral administration after the first immunization. The antibody titers of the lens group mostly stayed lower than those of BSA group (FIGS. 3 and 5).

From the above results, it was clarified that administration of lens homogenate before and/or after immunization with .beta.-crystallin suppressed increase in antibody titer of sera against antigen. It is preferable to start administration of the preparation of the present invention prior to immunization, and continue administration even after immunization, so that an increase in the antibody titers can be significantly suppressed. Formulation Example 1 ______________________________________ Formulation of tablets! Recombinant yeast (Sasccharomyces cerevisiae).sup.1) 80% Crystalline cellulose    1% Lactose                  10% Corn starch              5% Anhydrous calcium phosphate 2% Hydroxypropylcellulose   1% Magnesium stearate       1% Total                    100% ______________________________________ .sup.1) Prepared by transformation of yeast to enable expression of crystallin, using a commercially available yeast transformation kit (Yeas Starter Kit, BioRad).

Tablets were prepared by a conventional method according to the above-mentioned formulation, and applied with an enteric coating by a conventional method to give enteric-coated tablets.

The pharmaceutical composition of the present invention containing, as an active ingredient, a lens antigen or a microorganism capable of expressing said antigen shows marked inhibitory effects on the increase of an anti-lens protein antibody titer. Therefore, it most probably treats or prevents cataract effectively, and delays onset of cataract. Thus, the composition is extremely useful for cataract patients and reserve patients of cataract. SEQUENCE LISTING (1) GENERAL INFORMATION: (iii) NUMBER OF SEQUENCES: 47 (2) INFORMATION FOR SEQ ID NO: 1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 215 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1: MetGluThrGlnAlaGluGlnGlnGluLeuGluThrLeuProThrThr 151015 LysMetAlaGlnThrAsnProThrProGlySerLeuGlyProTrpLys 202530 IleThrIleTyrAspGlnGluAsnPheGlnGlylysArgMetGluPhe 354045 ThrSerSerCysProAsnValSerGluArgSerPheAspAsnValArg 505560 SerLeuLysValGluSerGlyAlaTrpIleGlyTyrGluHisThrSer 65707580 PheCysGlyGlnGlnPheIleLeuGluArgGlyGluTyrProArgTrp 859095 AspAlaTrpSerGlySerAsnAlaTyrHisMetGluArgLeuMetSer 100105110 PheArgProPheCysSerAlaAsnHisLysGluSerLysMetThrIle 115120125 PheGluLysGluAsnPheIleGlyArgGlnTrpGluIleSerAspAsp 130135140 TyrProSerLeuGlnAlaMetGlyTrpPheAsnAsnGluValGlySer 145150155160 MetLysIleGlnSerGlyAlaTrpValCysTyrHisTyrLeuGlyTyr 165170175 ArgGlyTyrGlnTyrIleLeuLysCysAspHisHisGluGlyAspTyr 180185190 LysHisTrpArgGluTrpGlySerHisAlaGlnThrSerGlnIleGln 195200205 SerIleArgArgIleGlnGln 210215 (2) INFORMATION FOR SEQ ID NO: 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: IleGluThrGlnAlaGlu 156 (2) INFORMATION FOR SEQ ID NO: 3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3: MetIleThrGlnAlaGlu 156 (2) INFORMATION FOR SEQ ID NO: 4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4: MetGluIleGlnAlaGlu 156 (2) INFORMATION FOR SEQ ID NO: 5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5: MetGluThrIleAlaGlu 156 (2) INFORMATION FOR SEQ ID NO: 6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: MetGluThrGlnIleGlu 156 (2) INFORMATION FOR SEQ ID NO: 7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7: MetGluThrGlnAlaIle 156 (2) INFORMATION FOR SEQ ID NO: 8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 205 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8: MetAlaSerAspHisGlnThrGlnAlaGlyLysProGlnSerLeuAsn 151015 ProLysIleIleIlePheGluGlnGluAsnPheGlnGlyHisSerHis 202530 GluLeuAsnGlyProCysProAsnLeuLysGluThrGlyValGluLys 354045 AlaGlySerValLeuValGlnAlaGlyProTrpValGlyTyrGluGln 505560 AlaAsnCysLysGlyGluGlnPheValPheGluLysGlyGluTyrPro 65707580 ArgTrpAspSerTrpThrSerSerArgArgThrAspSerLeuSerSer 859095 LeuArgProIleLysValAspSerGlnGluHisLysIleIleLeuTyr 100105110 GluAsnProAsnPheThrGlyLysLysMetGluIleIleAspAspAsp 115120125 ValProSerPheHisAlaHisGlyTyrGlnGluLysValSerSerVal 130135140 ArgValGlnSerGlyThrTrpValGlyTyrGlnTyrProGlyTyrArg 145150155160 GlyLeuGlnTyrLeuLeuGluLysGlyAspTyrLysAspSerSerAsp 165170175 PheGlyAlaProHisProGlnValGlnSerValArgArgIleArgAsp 180185190 MetGlnTrpHisGlnArgGlyAlaPheHisProSerAsn 195200205 (2) INFORMATION FOR SEQ ID NO: 9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 12 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9: GlyLeuThrGluThrGlnAlaGluAlaIleLeuGlu 151012 (2) INFORMATION FOR SEQ ID NO: 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 12 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10: MetGlnTyrHisTyrLeuGlyArgThrGlyTyrThr 151012 (2) INFORMATION FOR SEQ ID NO: 11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 12 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11: AspPheAlaThrIlePheGluLysAsnAlaPheLeu 151012 (2) INFORMATION FOR SEQ ID NO: 12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 12 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12: GlnLysLeuGlyProTrpLysArgProValAlaTyr 151012 (2) INFORMATION FOR SEQ ID NO: 13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13: MetGluThrGlnAlaGluGlnGlnGluLeuGluThrLeuProThrThr 151015 LysMetAla 19 (2) INFORMATION FOR SEQ ID NO: 14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14: ThrThrLysMetAlaGlnThrAsnProThrProGlySerLeuGlyPro 151015 TrpLysIle 19 (2) INFORMATION FOR SEQ ID NO: 15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15: GlyProTrpLysIleThrIleTyrAspGlnGluAsnPheGlnGlylys 151015 ArgMetGlu 19 (2) INFORMATION FOR SEQ ID NO: 16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16: GlylysArgMetGluPheThrSerSerCysProAsnValSerGluArg 151015 SerPheAsp 19 (2) INFORMATION FOR SEQ ID NO: 17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17: GluArgSerPheAspAsnValArgSerLeuLysValGluSerGlyAla 151015 TrpIleGly 19 (2) INFORMATION FOR SEQ ID NO: 18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18: GlyAlaTrpIleGlyTyrGluHisThrSerPheCysGlyGlnGlnPhe 151015 IleLeuGlu 19 (2) INFORMATION FOR SEQ ID NO: 19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19: GlnPheIleLeuGluArgGlyGluTyrProArgTrpAspAlaTrpSer 151015 GlySerAsn 19 (2) INFORMATION FOR SEQ ID NO: 20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20: TrpSerGlySerAsnAlaTyrHisMetGluArgLeuMetSerPheArg 151015 ProPheCys 19 (2) INFORMATION FOR SEQ ID NO: 21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21: PheArgProPheCysSerAlaAsnHisLysGluSerLysMetThrIle 151015 PheGluLys 19 (2) INFORMATION FOR SEQ ID NO: 22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22: ThrIlePheGluLysGluAsnPheIleGlyArgGlnTrpGluIleSer 151015 AspAspTyr 19 (2) INFORMATION FOR SEQ ID NO: 23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23: IleSerAspAspTyrProSerLeuGlnAlaMetGlyTrpPheAsnAsn 151015 GluValGly 19 (2) INFORMATION FOR SEQ ID NO: 24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24: AsnAsnGluValGlySerMetLysIleGlnSerGlyAlaTrpValCys 151015 TyrHisTyr 19 (2) INFORMATION FOR SEQ ID NO: 25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25: ValCysTyrHisTyrLeuGlyTyrArgGlyTyrGlnTyrIleLeuLys 151015 CysAspHis 19 (2) INFORMATION FOR SEQ ID NO: 26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26: LeuLysCysAspHisHisGluGlyAspTyrLysHisTrpArgGluTrp 151015 GlySerHis 19 (2) INFORMATION FOR SEQ ID NO: 27: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27: GluTrpGlySerHisAlaGlnThrSerGlnIleGlnSerIleArgArg 151015 IleGlnGln 19 (2) INFORMATION FOR SEQ ID NO: 28: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28: MetGluThrGlnAlaGlu 156 (2) INFORMATION FOR SEQ ID NO: 29: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29: GlnGlnGluLeuGluThr 156 (2) INFORMATION FOR SEQ ID NO: 30: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30: LeuProThrThrLysMetAla 157 (2) INFORMATION FOR SEQ ID NO: 31: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31: MetAlaSerAspHisGlnThrGlnAlaGlyLysProGlnSerLeuAsn 151015 Pro 17 (2) INFORMATION FOR SEQ ID NO: 32: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32: GlnSerLeuAsnProLysIleIleIlePheGluGlnGluAsnPheGln 151015 Gly 17 (2) INFORMATION FOR SEQ ID NO: 33: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33: GluAsnPheGlnGlyHisSerHisGluLeuAsnGlyProCysProAsn 151015 Leu 17 (2) INFORMATION FOR SEQ ID NO: 34: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34: ProCysProAsnLeuLysGluThrGlyValGluLysAlaGlySerVal 151015 Leu 17 (2) INFORMATION FOR SEQ ID NO: 35: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35: AlaGlySerValLeuValGlnAlaGlyProTrpValGlyTyrGluGln 151015 Ala 17 (2) INFORMATION FOR SEQ ID NO: 36: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36: GlyTyrGluGlnAlaAsnCysLysGlyGluGlnPheValPheGluLys 151015 Gly 17 (2) INFORMATION FOR SEQ ID NO: 37: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37: ValPheGluLysGlyGluTyrProArgTrpAspSerTrpThrSerSer 151015 Arg 17 (2) INFORMATION FOR SEQ ID NO: 38: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38: TrpThrSerSerArgArgThrAspSerLeuSerSerLeuArgProIle 151015 Lys 17 (2) INFORMATION FOR SEQ ID NO: 39: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39: LeuArgProIleLysValAspSerGlnGluHisLysIleIleLeuTyr 151015 Glu 17 (2) INFORMATION FOR SEQ ID NO: 40: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40: IleIleLeuTyrGluAsnProAsnPheThrGlyLysLysMetGluIle 151015 Ile 17 (2) INFORMATION FOR SEQ ID NO: 41: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41: LysMetGluIleIleAspAspAspValProSerPheHisAlaHisGly 151015 Tyr 17 (2) INFORMATION FOR SEQ ID NO: 42: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42: HisAlaHisGlyTyrGlnGluLysValSerSerValArgValGlnSer 151015 Gly 17 (2) INFORMATION FOR SEQ ID NO: 43: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43: ArgValGlnSerGlyThrTrpValGlyTyrGlnTyrProGlyTyrArg 151015 Gly 17 (2) INFORMATION FOR SEQ ID NO: 44: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44: ProGlyTyrArgGlyLeuGlnTyrLeuLeuGluLysGlyAspTyrLys 151015 Asp 17 (2) INFORMATION FOR SEQ ID NO: 45: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45: GlyAspTyrLysAspSerSerAspPheGlyAlaProHisProGlnVal 151015 Gln 17 (2) INFORMATION FOR SEQ ID NO: 46: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46: HisProGlnValGlnSerValArgArgIleArgAspMetGlnTrpHis 151015 Gln 17 (2) INFORMATION FOR SEQ ID NO: 47: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (A) DESCRIPTION: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47: ArgIleArgAspMetGlnTrpHisGlnArgGlyAlaPheHisProSer 151015 Asn 17 __________________________________________________________________________

## Claims

1. A suppressant of lens cell-damaging immune response, comprising a microorganism transformed with an expression vector having a DNA encoding .beta.-crystallin and a pharmaceutically acceptable carrier.

2. The suppressant claim 1, which is in the form of a preparation for oral administration.

3. The suppressant of claim 2, which is in the form of a preparation for intestinal absorption.

4. The suppressant of claims 1, 2 or 3, which is an agent for the therapy, prophylaxis or retardation of onset of cataract.

5. A method for suppressing lens cell-damaging immune response in a mammal, comprising orally administering an effective amount of a .beta.-crystallin to said mammal.

6. A method for suppressing lens cell-damaging immune response in a mammal, comprising orally administering, to said mammal, an effective amount of a microorganism transformed with an expression vector having a DNA encoding .beta.-crystallin.

7. The method of claim 5 or 6, wherein said .beta.-crystallin microorganism is in the form of a preparation for intestinal absorption.

8. The method of claim 5 or 6, which is for the therapy, prophylaxis or retardation of onset of cataract.

9. A method for suppressing lens cell-damaging immune response in a mammal, comprising orally administering an effective amount of a lens homogenate to said mammal.

10. The method of claim 9, wherein said homogenate is in the form of a preparation for intestinal absorption.

11. The method of claim 9, which is for the therapy, prophylaxis or retardation of onset of cataract.